Werewolf Therapeutics (HOWL) EBITDA (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly EBITDA of $7.2 million for Q2 2026, up 140.8% year-over-year from $3.0 million in Q2 2025, and up 153.94% on a QoQ basis from -$13.3 million in Q1 2026.
Werewolf Therapeutics (HOWL) EBITDA (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported EBITDA for 7 years, with the latest figure at $7.2 million in Q2 2026.
- EBITDA for Q2 2026 came in at $7.2 million, up 140.8% year-over-year; the trailing twelve-month figure through Jun 2026 was -$31.3 million (up 57.19% YoY), and the FY2025 annual result was -$60.7 million, up 17.55% from the prior year.
- EBITDA advanced to $7.2 million in Q2 2026, from -$13.3 million in the prior quarter.
- Over five years, EBITDA peaked at $7.2 million in Q2 2026 and troughed at -$20.3 million in Q4 2024.
- A 5-year average of -$13.2 million and a median of -$14.1 million in 2022 frame the typical range for EBITDA.
- The widest annual swing landed in 2024, when EBITDA tumbled 212.51%; it then jumped 140.8% in 2026.
- A 5-year view of EBITDA shows it stood at -$13.2 million in 2022, then advanced by 1.65% to -$13.0 million in 2023, then plunged by 56.98% to -$20.3 million in 2024, then jumped by 53.72% to -$9.4 million in 2025, then jumped by 176.0% to $7.2 million in 2026.
- Per Business Quant data, the three most recent EBITDA figures were $7.2 million in Q2 2026, -$13.3 million in Q1 2026, and -$9.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Werewolf Therapeutics | 20.90 Mn | 20.90 Mn | - | 7.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.16 Mn |
| Mar 31, 2026 | -13.27 Mn |
| Dec 31, 2025 | -9.42 Mn |
| Sep 30, 2025 | -15.73 Mn |
| Jun 30, 2025 | -17.54 Mn |
| Mar 31, 2025 | -17.99 Mn |
| Dec 31, 2024 | -20.35 Mn |
| Sep 30, 2024 | -17.12 Mn |
| Jun 30, 2024 | -18.96 Mn |
| Mar 31, 2024 | -17.16 Mn |
| Dec 31, 2023 | -12.96 Mn |
| Sep 30, 2023 | -9.25 Mn |
| Jun 30, 2023 | -6.07 Mn |
| Mar 31, 2023 | -12.22 Mn |
| Dec 31, 2022 | -13.18 Mn |
| Sep 30, 2022 | -12.54 Mn |
| Jun 30, 2022 | -14.97 Mn |
| Mar 31, 2022 | -15.37 Mn |
| Dec 31, 2021 | -17.88 Mn |
| Sep 30, 2021 | -13.80 Mn |